An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Myrbetriq

Chemical Namemirabegron
Dosage FormTablets (oral; 25mg, 50mg)
Drug ClassReceptor agonists
SystemUrinary
CompanyAstellas Pharma US
Approval Year2012

Indication

  • For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Last updated on 12/15/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Myrbetriq (mirabegron) Prescribing Information2012Astellas Pharma US Inc., Northbrook, IL
Document TitleYearSource
The use of mirabegron in neurogenic bladder: a systematic review. 2020World Journal of Urology
Comparative safety and efficacy of treatments for overactive bladder among older adults: A network meta‑analysis.2020Drugs and Aging
The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: A network meta-analysis.2019Urology
Updating the evidence on drugs to treat overactive bladder: a systematic review.2019International Urogynecology Journal
Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network meta-analysis.2018European Urology
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.2018BMJ Open
Systematic review of combination drug therapy for non-neurogenic lower urinary tract symptom. 2018European Urology
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis.2017BJU International
Document TitleYearSource
Diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adults: an AUA/SUFU guideline (2019).2019American Urological Association
CUA guideline on adult overactive bladder.2017Canadian Urological Association